| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Proqr Therapeutics N.V. (PRQR) has 2 insiders with recent SEC Form 4 filings, including 2 buys and 0 sells. PRQR is classified in the Biotechnology industry within the Healthcare sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 300.0K | $564.0K | +150.0K | |
| CEO | 300.0K | $564.0K | +150.0K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | Filius Bart | Director | Buy | 150,000 | $1.72 | $257,925.00 | +100.0% | |
| Jul 9, 2026 | De Boer Daniel Anton | Chief Executive Officer | Buy | 150,000 | $1.74 | $261,000.00 | +100.0% |